Stockreport

CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024

CYTODYN INC  (CYDY) 
NASDAQ:AMEX Investor Relations: ir.cytodyn.com
PDF VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 [Read more]